Pharsight

Yupelri patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7910608 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US7585879 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US7288657 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Dec, 2025

(1 year, 6 months from now)

US9765028 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(6 years from now)

US10550081 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(6 years from now)

US11858898 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(6 years from now)

US8541451 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Aug, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7521041 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US10106503 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US10343995 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US8053448 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US11247969 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US8273894 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US7550595 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US8034946 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US7491736 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(8 months from now)

US11691948 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(6 years from now)

US11008289 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(6 years from now)

US11484531 MYLAN IRELAND LTD Methods for treating chronic obstructive pulmonary disease
Oct, 2039

(15 years from now)

Yupelri is owned by Mylan Ireland Ltd.

Yupelri contains Revefenacin.

Yupelri has a total of 19 drug patents out of which 0 drug patents have expired.

Yupelri was authorised for market use on 09 November, 2018.

Yupelri is available in solution;inhalation dosage forms.

Yupelri can be used as for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd).

Drug patent challenges can be filed against Yupelri from 09 November, 2022.

The generics of Yupelri are possible to be released after 23 October, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 09, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using REVEFENACIN ingredient

NCE-1 date: 09 November, 2022

Market Authorisation Date: 09 November, 2018

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

How can I launch a generic of YUPELRI before it's drug patent expiration?
More Information on Dosage

YUPELRI family patents

Family Patents